New combo therapy aims to save bladders in cancer fight
NCT ID NCT05975307
First seen Dec 12, 2025 · Last updated Apr 24, 2026 · Updated 15 times
Summary
This study tests a treatment plan for muscle-invasive bladder cancer that avoids removing the bladder. Patients first receive chemotherapy plus an immunotherapy drug (toripalimab), followed by radiation therapy with more immunotherapy. The goal is to see if this combination can destroy the cancer while keeping the bladder intact. About 71 adults aged 18-75 with specific stages of bladder cancer are taking part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RADIOTHERAPY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer Center, Sun Yat-sen University
Guangzhou, Guangdong, 510060, China
Conditions
Explore the condition pages connected to this study.